GlassScriptPhysician profile
Amy Jane Mullin
NPI 1619572823
$9,587.09
in general payments reported to CMS, 2019-2025
50 companies · $2,169 in 2025
The $2,169 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,408 · 2022: $2,048 · 2023: $1,935 · 2024: $2,026 · 2025: $2,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,130.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,331.02 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $945.40 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $820.94 | 2021-2024 | Farxiga |
| Corcept Therapeutics | $602.61 | 2021-2025 | Korlym |
| Amgen INC. | $583.96 | 2021-2025 | Repatha, Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $523.24 | 2022-2025 | |
| Cequr Corporation | $388.96 | 2023-2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $379.34 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $344.20 | 2021-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $283.46 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $236.03 | 2022-2025 | Gvoke Hypopen |
| Insulet Corporation | $226.47 | 2021-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $225.23 | 2022-2025 | |
| Dexcom, INC. | $204.31 | 2022-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $203.85 | 2023-2025 | Isturisa |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.51 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $191.18 | 2021-2023 | Steglujan, Steglatro |
| Ibsa Pharma INC. | $190.12 | 2021-2025 | Tirosint, Licart, Licart |
| Amarin Pharma, INC. | $181.50 | 2021 | |
| Medtronic, INC. | $175.08 | 2022-2025 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $157.66 | 2023-2025 | Yorvipath |
| Madrigal Pharmaceuticals | $119.28 | 2025 | Rezdiffra |
| Esperion Therapeutics, INC. | $114.49 | 2021-2025 | Nexletol |
| Radius Health, INC. | $113.04 | 2024-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $79.14 | 2022-2024 | Strensiq |
| Ascensia Diabetes Care US INC. | $72.28 | 2024 | |
| Beta Bionics, INC. | $71.23 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ultragenyx Pharmaceutical INC. | $63.95 | 2022-2025 | Crysvita |
| Abbvie INC. | $62.95 | 2021-2022 | |
| Pfizer INC. | $59.82 | 2021-2022 | |
| Horizon Therapeutics Plc | $39.42 | 2023 | Tepezza |
| Amneal Pharmaceuticals LLC | $38.53 | 2022-2023 | Unithroid |
| Amryt Pharma Holdings LTD | $33.96 | 2022 | |
| Lifescan, INC. | $27.18 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $27.18 | 2023-2024 | Contrave, Nexletol, Nexlizet |
| Siemens Medical Solutions USA, INC. | $23.04 | 2021 | |
| Alvogen INC | $23.00 | 2025 | Teriparatide |
| Rgh Enterprises LLC | $22.57 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $20.22 | 2022 | |
| Averitas Pharma INC. | $19.98 | 2025 | Qutenza |
| Intuity Medical INC | $19.61 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Antares Pharma, INC. | $17.98 | 2022 | |
| Acerus Pharmaceuticals Corporation | $17.61 | 2022 | |
| Abbott Laboratories | $17.35 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $15.93 | 2021 | |
| Sequel Med Tech, LLC | $15.68 | 2025 | Twiist |
| Lexicon Pharmaceuticals, INC. | $15.33 | 2024 | |
| Renalytix Ai, INC. | $14.44 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $12.63 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Mullin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.